Phase I injectable
Metsera Emerges with $290M to Rival Obesity Pharmaceutical Giants Lilly and Novo
Metsera, $290M funding, Obesity treatment, Challenge Lilly and Novo, GLP-1 receptor agonist (Phase I injectable)
Actionable Insights Powered by AI
Metsera, $290M funding, Obesity treatment, Challenge Lilly and Novo, GLP-1 receptor agonist (Phase I injectable)